Next Article in Journal
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
Previous Article in Journal
Genetic Modification of T Cells
Previous Article in Special Issue
Innate Lymphoid Cells in Tumor Immunity
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2016, 4(2), 10;

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Center of Experimental Therapeutics, Ludwig Center for Cancer Res, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland
Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland
Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Author to whom correspondence should be addressed.
Academic Editor: Ghaith Bakdash
Received: 21 March 2016 / Revised: 15 April 2016 / Accepted: 19 April 2016 / Published: 3 May 2016
(This article belongs to the Special Issue Dendritic Cells and Cancer Immunotherapy)
Full-Text   |   PDF [1351 KB, uploaded 3 May 2016]   |  


Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the disease is usually diagnosed at an advanced stage, its prognosis remains very poor. Clearly, there is a critical need for new treatment options, and immunotherapy is one attractive alternative. Prophylactic vaccines for prevention of infectious diseases have led to major achievements, yet therapeutic cancer vaccines have shown consistently low efficacy in the past. However, as they are associated with minimal side effects or invasive procedures, efforts directed to improve their efficacy are being deployed, with Dendritic Cell (DC) vaccination strategies standing as one of the more promising options. On the other hand, recent advances in our understanding of immunological mechanisms have led to the development of successful strategies for the treatment of different cancers, such as immune checkpoint blockade strategies. Combining these strategies with DC vaccination approaches and introducing novel combinatorial designs must also be considered and evaluated. In this review, we will analyze past vaccination methods used in ovarian cancer, and we will provide different suggestions aiming to improve their efficacy in future trials. View Full-Text
Keywords: ovarian cancer; cancer vaccines; dendritic cell vaccination ovarian cancer; cancer vaccines; dendritic cell vaccination

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Martin Lluesma, S.; Wolfer, A.; Harari, A.; Kandalaft, L.E. Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines 2016, 4, 10.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top